Product Managers Are the Cool Kids Now

Key takeaways: Something has changed in how serious software organizations operate, and it isn’t getting enough airtime. The decisions that shape what ships, what gets killed, and what gets pushed are moving from project managers to product managers. As Planview’s Chief Product Officer, Louise Allen, put it at Pendomonium recently: “Product managers are the cool...

After the Plan: How Portfolio Visibility Carries Strategy Through Delivery

In complex portfolio environments, strong prioritization decisions are only as effective as the organization’s ability to sustain alignment during execution. Even when initiatives are evaluated rigorously, ranked objectively, and aligned to capacity targets, execution can drift if priorities, plans, dependencies, and risks are not consistently visible across teams and leadership. This blog post concludes the...

How to Turn Portfolio Priorities into Achievable Targets

Organizations invest significant effort in prioritizing initiatives. Strategic alignment is defined. Financial impact is evaluated. Risk and feasibility are assessed. A ranked portfolio takes shape, reflecting enterprise objectives and leadership intent. However, even well-prioritized portfolios can break down during planning. As funding decisions are made and delivery plans begin to form, gaps emerge. Total investment...

Why New Software Won’t Fix Your Broken Portfolio

Editor’s Note: This blog post launches a new series on software implementation. We’re sharing these insights – gleaned from years of working alongside Planview customers on hundreds of unique implementations – to support leaders and teams in finding lasting software success. Today, we hear from Amichai Faran, Director, Planview Evolve Advisory Services.

Planview and Ozmosi: Bringing AI-Powered Insight to Pharmaceutical Portfolio Decisions

Pharmaceutical organizations are under increasing pressure to make faster, smarter R&D decisions in an environment defined by complexity, uncertainty, and constant change. Making the environment even more vulnerable – and volatile – is the looming “patent cliff” for some of the world's best-selling drugs, which some analysts predict will trigger up to $350 billion in losses by 2032, according to CNBC.